GlassScriptPhysician profile
William Larry Gluck
NPI 1053316349
$2,853.12
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $492 · 2021: $261 · 2022: $716 · 2023: $389 · 2024: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $567.09 | 2019-2023 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $396.38 | 2019-2023 | Opdivo |
| Pfizer INC. | $233.65 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $215.39 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $211.92 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $151.28 | 2020-2022 | |
| Incyte Corporation | $139.13 | 2020-2022 | |
| Stemline Therapeutics INC. | $122.63 | 2022 | |
| Mirati Therapeutics, INC. | $121.84 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $121.84 | 2020 | |
| Springworks Therapeutics, INC. | $121.80 | 2024 | Ogsiveo |
| Amgen INC. | $109.26 | 2019 | |
| Merck Sharp & Dohme LLC | $108.81 | 2019 | |
| Kite Pharma, INC. | $94.26 | 2019 | |
| Seagen INC. | $75.53 | 2023 | Adcetris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.39 | 2023-2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gluck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.